A number of classes of proteins have been engineered for high stability using consensus sequence design methods. Here we describe the engineering of a novel albumin binding domain (ABD) threehelix bundle protein. The resulting engineered ABD molecule, called ABDCon, is expressed at high levels in the soluble fraction of Escherichia coli and is highly stable, with a melting temperature of 81.5°C. ABDCon binds human, monkey and mouse serum albumins with affinity as high as 61 pM. The solution structure of ABDCon is consistent with the three-helix bundle design and epitope mapping studies enabled a precise definition of the albumin binding interface. Fusion of a 10 kDa scaffold protein to ABDCon results in a long terminal half-life of 60 h in mice and 182 h in cynomolgus monkeys. To explore the link between albumin affinity and in vivo exposure, mutations were designed at the albumin binding interface of ABDCon yielding variants that span an 11 000-fold range in affinity. The PK properties of five such variants were determined in mice in order to demonstrate the tunable nature of serum half-life, exposure and clearance with variations in albumin binding affinity.
Introduction
Rapid elimination of biotherapeutic molecules from the blood stream can contribute to limited clinical effectiveness or the need for frequent dosing of patients. One major route of elimination is renal clearance via glomerular filtration, a process mostly associated with therapeutics of molecular weight <50 000 Da (Kontermann, 2011) . To overcome this limitation, a number of technologies have been introduced to increase the hydrodynamic radius of the therapeutic molecule above the threshold for kidney filtration, such as modification with polyethylene glycol or other polymers and production of fusion proteins (Kontermann, 2011) .
Production of fusion proteins with the Fc-fragment of IgG often results in long serum half-life due not only to increased size, but also as a result of antibody recycling through FcRn (Kuo et al., 2010) . TNF receptor 2, LFA-3, CTLA-4, IL-1 receptor and TPO-mimetic peptides are all FDA approved therapies produced as Fc-fusions (Kontermann, 2011) . In addition to IgG, serum albumin also exhibits a long half-life in vivo (∼19 days in humans) due to FcRn recycling. At a concentration of ∼40 g/l (606 µM), human serum albumin (HSA) is the most abundant protein found in the blood. In addition to a long half-life, biodistribution studies suggest that albumin may distribute within the body to areas important for targeting of disease, such as sites of inflammation or tumors (Wunder et al., 2003; Stork et al., 2009) . Thus, fusion to HSA has been successfully used to extend the serum half-life of a number of therapeutic peptides or proteins, including interferon alpha (Flisiak and Flisiak, 2010) , human growth hormone (Osborn et al., 2002) , coagulation factor IX (Metzner et al., 2009) , coagulation factor VIIa (Metzner et al., 2009) , insulin (Duttaroy et al., 2005) , urokinase (Breton et al., 1995) , hirudin (Sheffield et al., 2001 ) and bispecific antibody fragments . Additionally, a recent study found that increasing the affinity of HSA to FcRn can further extend serum half-life in vivo (Andersen et al., 2014) .
An alternative method to take advantage of the long serum half-life of albumin is to produce therapeutic proteins as fusions to peptides or protein domains that bind to serum albumin in the blood stream. Albumin binding moieties have been selected from phage display peptide libraries (Dennis et al., 2002 (Dennis et al., , 2007 and Vhh and dAb antibody fragment libraries (Coppieters et al., 2006; Holt et al., 2008; Walker et al., 2010) . In addition, a number of naturally occurring protein domains from bacteria are known to interact with albumin, presumably to enable distribution throughout the host organism. These three-helix bundle domains have a molecular weight of ∼6 kDa and interact with serum albumin primarily along one face of the bundle (Johansson et al., 1995 (Johansson et al., , 2002 Makrides et al., 1996; Lejon et al., 2004; Cramer et al., 2007) . One such domain, a fragment of streptococcal protein G, which binds to HSA with an affinity of 1 nM (GI48-GA3) (Makrides et al., 1996) , has been widely used to extend the serum half-life of proteins. Fusion to this domain has been shown to extend the half-life of soluble complement receptor type 1 (Makrides et al., 1996) , a bispecific antibody , Pf155/RESA (Ståhl et al., 1989) and Affibody scaffold molecules (Andersen et al., 2011; Orlova et al., 2013; Malm et al., 2014) .
In addition to altering the pharmacokinetic properties of a therapeutic domain, the biophysical properties of the fusion protein must be sufficient to enable large scale expression, purification and storage. More specifically, simple production processes, high solubility and stability of therapeutic proteins remain particularly challenging (Kozlowski and Swann, 2006) . One approach that has been successfully applied for the design of highly stable proteins is consensus engineering (Knappik et al., 2000; Lehmann et al., 2000; Lehmann and Wyss, 2001; Forrer et al., 2004; Steipe, 2004; Dai et al., 2007; Jacobs et al., 2012) . Stabilization of proteins by consensus design is based on the principle that randomly occurring stabilizing mutations are rare compared with destabilizing mutations during evolution unless a positive selective pressure is applied to maintain stability. Thus, highly conserved sequence positions of homologs proteins are thought to contribute further to protein stability to those where no clear consensus sequence is found (Steipe et al., 1994; Steipe, 2004) . Here we present the design and structure of a consensus albumin binding protein that exhibits high thermal stability and high affinity binding to serum albumins from a number of species. Furthermore, fusion of this domain to a short-lived scaffold molecule significantly extends the pharmacokinetic properties of the fusion protein in both mice and cynomolgus monkeys. Finally, we describe an engineering strategy that allows for tunable pharmacokinetics and exposure of these fusion molecules using modified ABD consensus domain proteins.
Results

Design of consensus sequence
A non-natural albumin binding domain (ABD) was designed by calculating a consensus sequence of three-helix bundle sequences deposited in the non-redundant protein database. In order to determine the consensus sequence, an ABD from Streptococcus sp. G148 protein G (G148-GA3) was used as a template sequence for a BLAST search (Altschul, 1990) against the non-redundant protein database using the website: http://blast.ncbi.nlm.nih.gov/Blast.cgi. A multiple sequence alignment was calculated from the 20 domains with the highest sequence similarity to G148-GA3 (Fig. 1) . No consideration was given to the species from which these molecules derive or whether the albumin binding properties have been confirmed. For the consensus sequence, referred to as ABDCon, the most common amino acid at each position in the sequence was chosen. Position 21 showed no true consensus, with Tyr occurring five times and six times. Phe, Leu and Lys were also found in the sequence alignment at this position. Without a clear consensus, Tyr was chosen instead of Ile for this position as this amino acid is found in previously characterized albumin binding molecules, GI48-GA, ALB8-GA and PSD1 (Fig. 1) . The lack of clear consensus at this position, however, argues that it is not as critical for stability thus no further analysis was completed. Pairwise sequence identities between ABDCon and the natural protein domains range from 45 to 82%.
Biophysical characterization
A synthetic gene encoding the amino acid sequence of ABDCon ( Fig. 1 ) was used to express the ABDCon protein in Escherichia coli with an N-terminal poly-histidine tag for purification ease. The consensus sequence was highly expressed in the soluble fraction of the cells, with a yield of >150 mg/l following affinity chromatography. The resulting protein was highly pure and monodisperse as judged by SDS-PAGE, analytical size exclusion chromatography (SEC) and LC-MS analysis ( Supplementary Fig. S1 ). ABDCon was shown to bind with high affinity to serum albumin purified from human, mouse or rhesus plasma using surface plasmon resonance. High affinity binding was measured to human (75 pM) and monkey (61 pM) albumin, with more than 40-fold weaker binding measured to murine albumin ( Fig. 2 and Table I ).
The use of consensus design frequently results in proteins with exceptional thermal stability. A melting temperature (T m ) of 81.5°C was measured for ABDCon at pH 7.4 in phosphate buffered saline using differential scanning calorimetry (DSC) (Fig. 3) . The thermal unfolding was found to be nearly fully reversible in a repeat scan of the same sample after cooling (Fig. 3a, red curve) .
The solution structure G148-GA3 (PDB 1GJS) predicts a disordered N-terminus for the sequence proceeding that of Position 1 in Fig. 1 (Johansson et al., 2002) . However, comparison to a series of other ABD structures, including that of one ABD domain from Finegoldia magna (ALB8-GA) revealed an extended N-terminal helix present in these domains (Lejon et al., 2004 (Lejon et al., , 2008 Cramer et al., 2007) . Thus, we sought to extend the N-terminal alpha helix of ABDCon in an attempt to increase stability further. Since no true consensus could be derived from our sequence alignments for this segment, we chose to add a six-residue sequence, TIDEWL, found in a number of natural ABDs. DSC studies demonstrated that inclusion of the N-terminal extension further increases the melting temperature of ABDCon from 81.5 to 90.9°C ( Supplementary Fig. S2 ).
Structural studies
The solution structure of ABDCon12, an ADBCon variant with a sixresidue N-terminal extension, was determined by NMR in order to confirm that the consensus protein retains the protein fold found in natural ABD proteins. The ensemble of calculated structures presented in Fig. 4 shows that ABDCon12 adopts the left-handed, antiparallel three-helix bundle structure typical of natural ABDs. Deviations between the ABDCon and natural ABD module structures occur primarily at the N-terminus and loops connecting the helices. According to epitope mapping experiments (see below), helix 2 and helix 3 are the primary contact between the ABD and serum albumin. At the N-terminus, only the Leu residue from the TIDEWL sequence appended to the ABDCon12 formally participates in backbone hydrogen bonding in helix 1. A significant portion of this peptide sequence completes a turn similar to that of an alpha helix, although backbone hydrogen bonding is absent. The side-chains of each residue from the N-terminal extension are solvent exposed, with ensemble analysis showing more rigid conformation for only the Trp and Leu residues.
Epitope mapping studies were carried out using 15 N HSQC NMR to identify ABDCon12 residues which directly interact with albumin. A titration of ABDCon12 with rabbit serum albumin (RSA) and subsequent backbone amide chemical shift perturbations illustrate residues and secondary structural elements involved in binding albumin. Helix 2 and helix 3 each have numerous residues interacting with RSA in contrast to only two N-terminal residues of helix 1 ( Supplementary  Fig. S3 ). These results indicate a similar binding interaction to that found in naturally occurring ABDs (Lejon et al., 2004) .
Pharmacokinetic studies
The ability of ABDCon to extend the serum half-life of a fusion protein was evaluated by producing a synthetic gene encoding a fusion of ABDCon to the c-terminus of a 10 kDa consensus FN3 domain protein, Tencon25 (Jacobs et al., 2012) . Tencon25 was chosen as the fusion molecule as it has been engineered for high stability and does not interact with any known target proteins. Thus, evaluation of ABDCon pharmacokinetics in vivo is unbiased by target binding or function of the fusion domain. The Tencon25 and ABDCon protein domains were fused by a (G 4 S) 2 peptide linker, with a poly-histidine tag incorporated at the C-terminus for purification purposes. Mice were treated with a single intravenous dose of Tencon25-ABDCon at 2 mg/kg and serum collected at time points from 10 min to 14 days postinjection. The concentration of Tencon25-ABDCon in serum was measured by ELISA using Anti-Tencon-specific antibodies.
Tencon25 is cleared with a terminal half-life of ∼40 min in mice due to its small size (data not shown). Fusion of Tencon25 to ABDCon extends the terminal half-life in mice to over 60 h ( Fig. 5 and Table IV ). In cynomolgus monkeys, Tencon25-ADCon has a terminal half-life of 182 h (note: cynomolgus monkey serum shares 100% sequence identify with rhesus serum albumin, Table I ) (Fig. 5 ).
Tunable serum exposure
As the ABDCon sequence described here binds to HSA with an affinity of 75 pM and an off-rate of 3.02E−5 s
, molecules fused to ABDCon will be largely bound to albumin following administration into circulation where the albumin concentration is very high. However, for some targets and fusions, it may be desirable for the therapeutic molecule to be bound less tightly to serum albumin. Ten ABDCon mutants were designed to lower the binding affinity of ABDCon for albumin by changing the presumed interaction surface between ABDCon and Albumin. ABDCon mutants were selected by examining the crystal structure of the ALB8-GA module bound to HSA (PDB code 1TF0) (Lejon et al., 2004) . Based on the crystal structure of the complex and our RSA epitope mapping, we assume ABDCon binds to human albumin in a manner similar to ALB80GA. Mutants were designed to decrease the affinity of ABDCon for albumin by disrupting hydrophobic contacts, introducing steric clashing, disrupting salt bridges or disrupting hydrogen bonding (Table II) . Changes introduced were designed to decrease binding affinity without changing the binding surface so dramatically that binding was abolished. Each mutant was expressed and purified from E.coli as described for ABDCon. Mutant ABDCon11 was found to be insoluble and thus excluded from further analysis. The affinities of each variant for human, mouse and rhesus serum albumin were determined by surface plasmon resonance (Table III) . All of the designed mutations led to decreases in affinity to human albumin with measured affinities ranged from 400 pM to 860 nM for HSA. All mutants also exhibited decreased affinity for murine albumin, from 21 nM to 1.6 µM.
Tencon25 was fused to ABDCon variants 3, 5, 7 and 9 in order to assess the correlation between ABDCon affinity for albumin and in vivo pharmacokinetics. This subset of variants was chosen in order to span a wide range of albumin affinities. The molecules were dosed into mice at 2 mg/kg as described above and analyzed using identical methods as described for the Tencon25-ABDCon fusion. A summary of the PK parameters obtained for these molecules is shown in Table IV . Our data demonstrate that the rate of clearance decreases as affinity for albumin is increased until reaching an affinity of 103 nM at which point, no large differences in PK parameters are obtained. Clearance rates and exposure (AUC) were highly dependent upon the binding affinity for albumin. Even the weakest binding molecule, Tencon25-ABDCon5, with an affinity of only 1.65 µM resulted in a terminal half-life of 33 h in mice. Relatively fast clearance rates for low affinity ABDCon variants 9 and 5 appear to correlate with the residence time for the ABDCon-albumin complex (Table IV) .
Discussion
Protein therapeutics offer numerous potential advantages over small molecule drugs in areas such as specificity and affinity for target binding, the ability to inhibit large protein-protein interactions, and the potential for long systemic serum half-lives. Although monoclonal antibodies remain the most significant player in protein therapeutics, peptides and newer therapeutic platforms called alternative scaffolds are of much importance to industrial and academic scientists. These alternative scaffold proteins are often derived from simpler, smaller proteins and enable potential advantages over traditional antibodies for some applications (Skerra, 2000) . The smaller size of these molecules may, however, be a disadvantage in applications where a long half-life and less frequent dosing are desirable. Here we present the design of a highly stable consensus ABD protein that can be attached to peptides and therapeutic proteins for extension of half-life in vivo. The consensus design was demonstrated to fold into a three-helix bundle structure similar to that of natural ABD molecules. Epitope mapping studies demonstrate that ABDCon interacts with serum albumin using a face of the three-helix bundle structure composed mostly helices 2 and 3 to interact with albumin, similar to naturally occurring complexes. ABDCon12 with the extended N-terminal helix exhibits a high thermal stability of 91°C, with incorporation of the N-terminal TIDEWL sequence of ABDCon12 increasing the thermal stability of ABDCon by almost 10°C. We hypothesize that the final Leu of this peptide sequence is most important for this increased stability as its backbone carbonyl forms a hydrogen bond with the backbone Introduce steric clash amine of Ala 4 (numbering of Fig. 1 ) allowing the alpha helix to be extended by one turn. These results compare favorably with other efforts to produce highly stable ABD proteins. An effort to increase the stability of G148-GA3 to alkaline conditions resulted in an increase in thermal stability of the natural domain from 70 to ∼80°C (Gülich et al., 2000) . An alternative study employed off-set recombinant PCR combined with phage display to shuffle the sequences of 16 ABDs and select PSD-1, a variant with an increased thermal stability of 85°C, as measured with circular dichroism (Rozak et al., 2006) . The authors of this study hypothesize that the major driver of this increased stability is the mutation of an isoleucine of G148-GA3 to lysine (residue 39 in Fig. 1 ) that displaces helix 3 in the G148-GA3 structure. Interestingly, this position is occupied by Lys in ABDCon as well as this position is well conserved among the homologs used for the sequence alignment. The NMR structure of ADBCon presented here shows helix 3 positioned closer to helix 2 as in the PSD-1 structure, suggesting a similar mechanism of stabilization. Additional, further comparisons of the molecular mechanism of ABDCon and PSD-1 variant stabilization are difficult at this time due to the low sequence identity of these two molecules. Of practical importance is the ease in creating consensus designs like ABDCon to engineer stable proteins. While the discovery of PSD-1 required the shuffling of various gene sequences and the creation and subsequent selections of a phage display library to produce a stable construct, only a single consensus ABD sequence was designed and later only one additional construct made to extend the N-terminal helix. The success of this engineering effort to obtain high thermal stability coincides with other highly efficient efforts at designing consensus proteins with good biophysical properties (Knappik et al., 2000; Lehmann et al., 2000; Lehmann and Wyss, 2001; Forrer et al., 2004; Steipe, 2004; Dai et al., 2007; Jacobs et al., 2012) . The ability to bind to serum albumins from various species is a critical attribute of ABDCon. While binding to HSA is necessary for future therapeutic purposes, binding to a wider range of albumin species is also important to conduct preclinical, toxicology and pharmacology experiments. ABDCon binds to HSA with an affinity of 75 pM, considerably tighter than that measured for some natural ABDs such as G148-GA (1.2 nM) and the ALB8-GA (3.1 nM) (Johansson et al., 2002; Jonsson et al., 2008) , but not as tight as the engineered ABD035 variant described previously, which binds to HSA with an affinity of 50-500 fM (Jonsson et al., 2008) . ABD035 was engineered to bind with such extraordinary affinity by incorporation of just seven mutations compared with the starting G148-GA domain. Interestingly, only two of these seven mutated positions are conserved with the ABDCon sequence (Lys28 and Lys39 numbering from Fig. 1 ) suggesting that there are many possible solutions for increasing the binding of ABDs to albumin. As the sequences of ADBCon and ABD035 are only 64% identical, and the structures of these molecules bound to albumin have not yet been solved, it is unfortunately difficult to determine which specific residues contribute to the differences in affinity between these two engineered variants further. ABDCon retains broadly specific albumin binding as demonstrated to human, mouse and rhesus monkey albumin here. Interestingly, the consensus sequence contains sequence Tyr21 which has been attributed with broad specificity in the G148-GA domain (Nilvebrant and Hober, 2013) . It is interesting to contemplate if the consensus design approach, in general terms, results in high affinity binding for target proteins. Indeed, previous studies with zinc finger peptides (Krizek et al., 1991) and heparin-binding peptides (Verrecchio et al., 2000) demonstrate increases in affinity from consensus design. The data presented here show high affinity binding from the consensus domain but it should be noted that not all of the affinities for the natural binding domains used in the design have been reported, and thus it is not clear if ABDCon has higher affinity than all natural domains. Although it seems likely that amino acids important for protein binding of natural protein domains will be conserved and thus well represented in a consensus design, and that stabilization in general may result in tighter binding by reducing entropy of binding, there does not yet exist sufficient evidence that such a consensus approach will generally be successful for engineering the binding affinity of natural proteins.
The natural ABDs have likely evolved to enable binding and release from albumin with kinetics appropriate to enable cellular uptake. ABDCon binds to rhesus monkey albumin with an affinity of 61 pM and provides a small fusion protein a terminal half-life of over 7.5 days in cynomologus monkeys. Importantly, binding to mouse albumin is retained, albeit at the weaker affinity of 3 nM. Our results demonstrate significant half-life extension in mice when using ABDCon variants that bind to MSA only very weakly (∼1.6 µM) in agreement with a previous study that investigated the serum half-life of various ABD variants (Hopp et al., 2010) . In that study, the PK of three GI48-ABD variants ranging in affinity for mouse albumin from ∼2 to 600 nM was determined, with the conclusion that only moderate changes in terminal half-life were observed, even for the lowest affinity molecule. In the data presented here, five ABDCon variants differing by only a single point mutation with affinities ranging from ∼3 nM to 1.6 µM were studied in mice. Although the weakest binding molecule (ABDCon5) was found to have a relatively long terminal half-life of 32 h in mice, inspection of the data in Fig. 5 and Table IV reveals that changes in affinity for MSA significantly affect other pharmacokinetic properties, most notably clearance rates and AUC. Thus although the calculation of terminal half-life is within a factor of 2 between the variants, the total exposure in serum (AUC measurement) for ABDCon5 was only ∼20% of that for the ABDCon fusion, with the ABDCon9 variant falling in between. In agreement with the previous study, ADBCon9, with an affinity of 550 nM shows similar changes in AUC as described for scDb-ADB-L, a molecule with a measured affinity of 634 nM (Hopp et al., 2010) .Thus, the conclusion from Hopp et al. regarding the effects of affinity of PK parameters may have been different if even weaker binding molecules were tested. Given the high concentration of albumin in serum, our data suggest that significant differences in serum exposure will require low affinity binding to albumin. The data described here demonstrate the ability to tune the PK properties of fusion molecules using different ABDCon variants. Indeed, some ABDCon variants appear to have a terminal half-life longer than that reported for murine albumin itself. Several possibilities exist for this apparent discrepancy: (i) non-covalent interaction binding to albumin means that such complexes are dynamic and half-life is not strictly limited to that of a single albumin molecule and (ii) comparison between half-life measurements assessed in different experiments can be complicated by the method use for data analysis. Rather, the data series presented here indicate that modulation of affinity for albumin can be used to modulate in vivo exposure. For many applications, longer PK is desirable. However, for some applications, like imaging studies or cytotoxic drug conjugates, the ability to tune exposure and clearance could be an important aspect of protein optimization. For years, the three-helix bundle ABD has served as a model system for protein engineering, resulting in the successful creation of many different variants with altered binding affinity, stability, specificity and serum half-life (reviewed in Nilvebrant and Hober, 2013) . Whereas previous efforts resulted in properties like ultra-high affinity at the expense of aggregation state and thermal stability (Jonsson et al., 2008) or high thermal stability without increased affinity (Rozak et al., 2006) , the ABDCon12 molecule provides a high binding affinity for human (75 pM) and mouse (1 nM) albumin while maintaining the highest reported ABD thermal stability (91°C). As with other consensus protein fusions (Jacobs et al., 2012) , we have collected anecdotal evidence suggesting that fusions of various proteins to ABDCon generally increases expression levels in E.coli, solubility, and overall stability (data not shown). Given these characteristics, as well as the high stability, tunable PK and demonstrated half-life extension in monkeys, we believe ABDCon to be an important tool for researchers looking to extend the serum half-life of peptides and proteins in vivo. In addition, the high stability and expression levels of ABDCon may make this molecule ideal for the creation of new three-helix bundle libraries. For example, such libraries could enable selection of novel molecules that bind to various targets similar to efforts engineering 'affibodies' with novel activities (Nord et al., 1995; Löfblom et al., 2010) or identification of proteins that can bind to therapeutic targets and albumin simultaneously (Nilvebrant et al., 2011) .
Materials and methods
Consenus design
All default settings were used for the BLAST search from the website http://blast.ncbi.nlm.nih.gov/Blast.cgi; expect threshold = 10, word size = 3, matrix = BLOSUM62, gap costs = existence 11, extension 1 and compositional adjustments = conditional compositional score matrix adjustment. The sequence of the Streptococcal Protein G ABD, accession number WP_003061108.1 residues 153-198. From this search, the 20 most closely related protein domains were selected to be included in a multiple sequence alignment in order to determine a consensus. Only non-redundant sequences were selected. Several protein accession numbers are listed multiple times in Fig. 1 , indicative that certain proteins contain several closely related domains. One member, PDS-1 in Fig. 1 , is a non-natural ABD derived by phage display and gene shuffling . A multiple sequence alignment was generated from the sequences listed using AlignX software (using all default settings).
Gene synthesis
The amino acid sequence of the ABD consensus (ABDCon) was back translated into a nucleic acid sequence encoding for ABDCon using preferred codons for E.coli expression and a synthetic gene produced (BlueHeron Biotechnologies). 5′ and 3′ DNA sequences were added to the synthetic gene sequence in order to add NdeI and XhoI sites for subcloning, as well as DNA sequences encoding for an N-terminal 8-His tag for protein purification. This gene was cloned into a pET26 vector (Novagen) for expression driven by a T7 promoter sequence and transformed into E.coli strain BL21(DE3) (Novagen). Synthetic genes encoding Tencon25-ABDCon fusion proteins were produced at DNA2.0. Gene fragments were cloned into a pJ401 bacterial expression vector driven by a T5 promoter.
Expression and purification
For expression of ABDCon and ABDCon fusions, LB media supplemented with 30 µg/ml kanamycin were inoculated with one colony and grown overnight at 37°C, 220 rpm shaking. The next day, the overnight culture was added to a 50-fold excess of Terrific Broth supplemented with 30 µg/ml kanamycin and the culture grown at 37°C, 220 rpm for 2.5 h. IPTG was added to a final concentration of 1 mM and the temperature reduced to 30°C to induce protein expression. Cells were harvested 14 h later by centrifugation at 4000 × g for 20 min and the cell pellets stored at −20°C. Frozen cell pellets were re-suspended in 5 ml of BugBuster HT (Novagen) per gram of wet pellet and gently mixed at room temperature for 30 min. The polyhistidine tagged ABDCon molecule was purified by Ni-NTA chromatography (GE Healthcare), eluting in a buffer of 50 mM sodium phosphate pH 7.4, 500 mM sodium chloride with a gradient of imidazole from a concentration of 10-250 mM imidazole. Fractions containing ABDCon were pooled and further purified by SEC using a Superdex75 16/60 column (GE Healthcare) with a mobile phase of PBS. Purity was assessed by SDS-PAGE, LC-MS and analytical SEC using a Superdex 5/150 column (GE Healthcare). Mass spectrometry determined the mass to be 6383 Da, in agreement with the theoretical mass of 6382 Da (Supplementary Fig. S1a ).
Production of labeled Tencon for NMR studies
ABDCon containing an N-terminal eight histidine tag and TEV protease cleavage site was transformed into E.coli BL21 DE3 RIL cells and cultured in 15N, 13C minimal media at 37°C. Expression was induced at 1.0 OD 600 nm with 1 mM IPTG; the culture was harvested 3 h after induction. ABDCon was also expressed in either 100% 15N, 5% 13C minimal media, 100% 15N, 1-13C minimal media, or 100% 15N, 13C, 50% D 2 O minimal media and purified using the same protocol.
Cells were lysed in 20 mM sodium phosphate pH 7.0, 500 mM NaCl, 20 mM imidazole buffer containing protease inhibitors and endonuclease, in two passes through a Microfluidics homogenizer. The lysate was centrifuged at 45 000 × g for 50 min at 4°C. The supernatant was loaded onto a GE Healthcare Lifesciences HisTrap Fast Flow column, the column was washed with 40 CV 20 mM sodium phosphate pH 7.0, 500 mM NaCl, 20 mM imidazole, and eluted in a linear gradient from 20 mM imidazole to 250 mM imidazole into a 96-well plate that contained sufficient 0.5 M EDTA to make fractions a final 5 mM EDTA concentration. Fractions were pooled and dialyzed into PBS containing 5 mM EDTA. The histidine tag was cleaved at room temperature for 4 h using TEV protease at an enzyme/substrate ratio of 1:50 (w/w). The cleaved pool was dialyzed into PBS and then incubated with Takara/Clontech Talon IMAC resin in batch mode for 4 h at 4°C. The supernatant, containing untagged ABDCon, was concentrated to 0.8 mM.
Determination of ABDCon structure
NMR experiments were performed using Bruker Avance and Varian Inova 500, 600 and 800-MHz cryo-probe equipped spectrometers. Isotopically enriched ABDCon12 (∼0.8 mM) was dissolved in aqueous buffer containing 10% 2 H 2 O, 20 mM MES at pH 6.5, 100 mM NaCl, 10 mM DTT and 0.002% NaN 3 . All spectra were collected at 298 K. 1 (Neri et al., 1989) .
Inter-proton distance restraints, based on through-space 1 H-1 H coupling, observed in NOESY spectra were automatically assigned using CYANA 2.1 (Güntert, 2004) . CYANA was used for initial structure generation followed by Rosetta refinement. Primary sequence was input to CYANA with seven cycles of combined automated NOESY assignment and structure calculation. Each cycle produced 1000 conformers using a simulated annealing algorithm with 10 000 torsion angle dynamics steps followed by 50 000 steps of energy minimization. Chemical shift data are used in the MFR fragment picking method during the first step of restrained CS-Rosetta refinement (Shen et al., 2008) . PDBStat was then used to convert CYANA-derived restraints to Rosetta format. Finally, 10 000 decoys were generated using NMR restraints by the Rosetta application AbinitioRelax. An ensemble of the 20 lowest rescore decoys constitutes the refined structure with coordinates deposited in the RCSB (2n35) 
Thermal stability measurements
ABDCon was concentrated to 2.175 mg/ml in PBS pH 7.4 and the thermal stability assessed by DSC. Stability data were generating by heating 400 µl of the ABDCon solution from 25 to 100°C at a scan rate of 1°C per minute in a VP-DSC instrument (MicroCal). A second identical scan was completed on the sample in order to assess the reversibility of thermal folding/unfolding. Data were fit to a two-state unfolding model in order to calculate the melting temperature. Figure 3 shows that ABDCon has a high thermal stability of 81.5°C in PBS and that folding is fully reversible.
ABDCon binding to albumin
The kinetics of ABDCon binding to HSA and mouse serum albumin were measured on a ProteOn XPR-36 (Bio-Rad) using GLC chips. Human, rhesus and murine serum albumins were purchased from Sigma (Catalog # A4327 for human, # A3559 for murine and # A4297 for rhesus) and re-suspended in PBS at different concentrations. Each serum albumin was directly immobilized on a ligand channel in the vertical orientation of a GLC chip via standard amine coupling at 2.1 µg/ml at pH 5.0 to obtain surfaces with ligand densities of 500-1000 resonance units. Binding of recombinant ABDCon was tested by flowing five different concentrations (e.g. 1 µM diluted in a 3-fold concentration series) as analytes simultaneously in the horizontal orientation over the immobilized serum albumin surfaces. The dissociation phases for all concentrations were monitored for 2 h at a flow rate of 100 µl/min using PBST (PBS, 0.005% Tween20) as running buffer. A sixth sample (buffer only) was injected to monitor the baseline stability. The surfaces were regenerated using one short pulse (18 µl) of 0.8% phosphoric acid. The raw response data were first processed by subtracting the buffer only responses and the non-specific binding between the analytes and the chip. Processed data of all five concentrations were globally fit to a 1:1 simple Langmuir binding model for each ligand surface.
PK studies
Female BALB/c mice (n = 3 per time point) were treated with a single intravenous dose of Tencon25-ABDCon variant at 2 mg/kg. Serum samples were collected over a course of 2 weeks. Naïve male cynomolgus monkeys (n = 3) were treated with a single intravenous dose of Tencon25-ABDCon12 at 3 mg/kg. Serum samples were collected over a course of 3 weeks. Serum samples were analyzed by ELISA. SA-Gold plates (Mesoscale Discovery, Catalog # L15SA) were blocked for 1 h with assay buffer. A mixture of biotinylated anti-Tencon antibody and ruthenium-labeled anti-Tencon antibody was prepared and added to the plates along with serum samples. Following a 2-h incubation, the plates were washed and read on an MSD Sector Imager, using MSD Read Buffer T (Catalog # R92TC). Results were initially obtained as electrochemiluminescence units, and were then interpolated from a standard curve prepared with known concentration of the appropriate Tencon-ABDCon variant. Non-compartmental analysis of the final data was performed using the PK Solver Excel Add-in (Zhang et al., 2010) to determine PK parameters. For the mouse study, the results for each molecule were compiled and evaluated as a single dataset to determine PK parameters, which is reported. For the cynomolgus monkey study, the PK parameters were determined for each monkey and the mean result ± SD is shown.
Supplementary data
Supplementary data are available at PEDS online.
